Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CERTOLIZUMAB PEGOL Cause Therapy interrupted? 3,209 Reports in FDA Database

Grow Your Own Natural Pharmacy at Home

Medicinal Garden Kit — 10 healing herbs, 4,818 seeds + step-by-step guide.

Get the Kit

According to the FDA Adverse Event Reporting System (FAERS), 3,209 reports of Therapy interrupted have been filed in association with CERTOLIZUMAB PEGOL (Cimzia). This represents 3.2% of all adverse event reports for CERTOLIZUMAB PEGOL.

3,209
Reports of Therapy interrupted with CERTOLIZUMAB PEGOL
3.2%
of all CERTOLIZUMAB PEGOL reports
14
Deaths
390
Hospitalizations

How Dangerous Is Therapy interrupted From CERTOLIZUMAB PEGOL?

Of the 3,209 reports, 14 (0.4%) resulted in death, 390 (12.2%) required hospitalization, and 6 (0.2%) were considered life-threatening.

Is Therapy interrupted Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CERTOLIZUMAB PEGOL. However, 3,209 reports have been filed with the FAERS database.

What Other Side Effects Does CERTOLIZUMAB PEGOL Cause?

Drug ineffective (23,838) Rheumatoid arthritis (17,782) Pain (13,929) Fatigue (11,438) Off label use (10,281) Rash (9,663) Alopecia (9,111) Maternal exposure during pregnancy (9,013) Arthralgia (8,993) Abdominal discomfort (8,615)

What Other Drugs Cause Therapy interrupted?

ADALIMUMAB (5,755) ETANERCEPT (3,397) RELUGOLIX (3,251) LENALIDOMIDE (2,724) UPADACITINIB (1,741) ABATACEPT (1,726) CLOZAPINE (1,722) AMIKACIN (1,283) TOFACITINIB (1,182) SECUKINUMAB (1,071)

Which CERTOLIZUMAB PEGOL Alternatives Have Lower Therapy interrupted Risk?

CERTOLIZUMAB PEGOL vs CERTOPARIN CERTOLIZUMAB PEGOL vs CETIRIZINE CERTOLIZUMAB PEGOL vs CETIRIZINE\PSEUDOEPHEDRINE CERTOLIZUMAB PEGOL vs CETRIMIDE CERTOLIZUMAB PEGOL vs CETRORELIX

Related Pages

CERTOLIZUMAB PEGOL Full Profile All Therapy interrupted Reports All Drugs Causing Therapy interrupted CERTOLIZUMAB PEGOL Demographics